Eli Lilly and Company v Pfizer Ireland Pharmaceuticals (No 3)

Link copied
Case Copied 4 min read

FEDERAL COURT OF AUSTRALIA

Eli Lilly & Company v Pfizer Ireland Pharmaceuticals (No 3) [2004] FCA 1085

INTELLECTUAL PROPERTY – patents – application to rely on experiments conducted in the United States as experimental proof – whether applicants concealed experimental evidence – whether respondents would be prejudiced if experiments could be relied on

Federal Court Rules, O 58 r 31

ELI LILLY & COMPANY & ORS V PFIZER IRELAND PHARMACEUTICALS & ANOR
V604 OF 2002

HEEREY J
16 AUGUST 2004
MELBOURNE


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

V604 OF 2002

BETWEEN:

ELI LILLY & COMPANY
FIRST APPLICANT/FIRST CROSS-RESPONDENT

ELI LILLY AUSTRALIA PTY LTD
ACN 000 233 992
SECOND APPLICANT/SECOND CROSS-RESPONDENT

ELI LILLY & COMPANY LIMITED
THIRD APPLICANT/THIRD CROSS-RESPONDENT

AND:

PFIZER IRELAND AND PHARMACEUTICALS
FIRST RESPONDENT/FIRST CROSS-CLAIMANT

PFIZER PTY LIMITED ACN 008 422 348
SECOND RESPONDENT/SECOND CROSS-CLAIMANT

JUDGE:

HEEREY J

DATE OF ORDER:

16 AUGUST 2004

WHERE MADE:

MELBOURNE

THE COURT ORDERS THAT:

  1. Leave be granted to the applicants/cross-respondents to rely on affidavits in admissible form substantially in accordance with the declarations of Dr Vincent Florio and Dr Philip Iverson annexed to the notice of motion dated 10 August 2004 as evidence derived from experimental proof of a matter as evidence in this proceeding.
  2. The applicants/cross-respondents pay the applicants costs of the motion.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

V604 OF 2002

BETWEEN:

ELI LILLY & COMPANY
FIRST APPLICANT/FIRST CROSS-RESPONDENT

ELI LILLY AUSTRALIA PTY LTD ACN 000 233 992
SECOND APPLICANT/SECOND CROSS-RESPONDENT

ELI LILLY & COMPANY LIMITED
THIRD APPLICANT/THIRD CROSS-RESPONDENT

AND:

PFIZER IRELAND AND PHARMACEUTICALS
FIRST RESPONDENT/FIRST CROSS-CLAIMANT

PFIZER PTY LIMITED ACN 008 422 348
SECOND RESPONDENT/SECOND CROSS-CLAIMANT

JUDGE:

HEEREY J

DATE:

16 AUGUST 2004

PLACE:

MELBOURNE

REASONS FOR JUDGMENT

  1. This is an application for leave to rely on evidence derived from experimental proof. Alternatively the applicants seek directions for the conduct of further experiments pursuant to O 58 r 31 of the Federal Court Rules.  The circumstances are described in the two affidavits of Mr Grant William Fisher sworn 10 and 11 August 2004 and the affidavit of Mr Stephen Marcus Stern sworn 16 August 2004.  I also refer to the applicants’ written submissions handed to me today.

  2. In my view there is no reasonable basis for inferring a deliberate course of concealment on the part of Eli Lilly.  The experiments of Dr Florio seem to have been conducted for a purpose quite unrelated to the present proceeding, that is to say for US Patent Office re-examination proceedings.  I think also it is reasonable to draw the conclusion that it was not until the letter of 5 April 2004 that it became clear to Lilly that the construction of claim 10 of the patent in suit referred to in that letter was to be relied on by Pfizer in the Australian proceeding. 

  3. It is true there has been less than admirable promptness between that date and…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Eli Lilly and Company v Pfizer Ireland Pharmaceuticals (No 3... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2004] FCA 1085
Decision Date

CaseChat Overview and Summary

Eli Lilly and Company, a pharmaceutical company, filed an application in the Federal Court of Australia against Pfizer Ireland Pharmaceuticals, another pharmaceutical company. The dispute centres on a patent for the drug olanzapine, used in the treatment of schizophrenia and related disorders. The Federal Court was tasked with determining the admissibility of certain affidavits in relation to the validity of the patent held by Eli Lilly. The affidavits were intended to be used as evidence derived from experimental proof in the proceeding.

The legal issues before the court were whether the affidavits in question could be admitted as evidence and, if so, under what conditions. The court needed to determine whether the affidavits met the criteria for admissibility as experimental proof and whether they should be allowed as evidence in the proceeding. The admissibility of such evidence is a matter of significant importance in patent litigation, where the ability to rely on experimental proof can influence the outcome of the case.

The court granted leave for the applicants/cross-respondents to rely on affidavits substantially in accordance with the declarations of Dr Vincent Florio and Dr Philip Iverson. These affidavits were deemed to be admissible as evidence derived from experimental proof, provided they met certain conditions. The court ordered that the applicants/cross-respondents bear the costs of the motion. The decision emphasised the importance of ensuring that the evidence is reliable and relevant to the issues at hand. The court's reasoning was based on the need to balance the protection of intellectual property rights with the need for fair and just proceedings in patent litigation.

Orders

Orders of the court

1. Leave be granted to the applicants/cross-respondents to rely on affidavits in admissible form substantially in accordance with the declarations of Dr Vincent Florio and Dr Philip Iverson annexed to the notice of motion dated 10 August 2004 as evidence derived from experimental proof of a matter as evidence in this proceeding.

2. The applicants/cross-respondents pay the applicants costs of the motion.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

HEEREY J

Ratio Decidendi

Legal Principle Established

Established by: HEEREY J